Jul 24, 2009 - CytRx Corporation, a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that its lead drug candidate tamibarotene has received official notification from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA) that a positive opinion was made regarding the application for orphan medicinal product for the treatment of acute promyelocytic leukemia (APL).
The details can be read here.
No comments:
Post a Comment